These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 9434921)
1. The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease. Scherer R; Kabatnik M; Erhard J; Peters J Intensive Care Med; 1997 Nov; 23(11):1150-8. PubMed ID: 9434921 [TBL] [Abstract][Full Text] [Related]
2. Procoagulant activity in patients with isolated severe head trauma. Scherer RU; Spangenberg P Crit Care Med; 1998 Jan; 26(1):149-56. PubMed ID: 9428558 [TBL] [Abstract][Full Text] [Related]
3. [The effect of substitution with AT III- and PPSB-concentrates in patients with terminal liver insufficiency]. Scherer R; Gille A; Erhard J; Paar D; Kox WJ Anaesthesist; 1994 Mar; 43(3):178-82. PubMed ID: 8179167 [TBL] [Abstract][Full Text] [Related]
4. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Hoffmann JN; Mühlbayer D; Jochum M; Inthorn D Crit Care Med; 2004 Sep; 32(9):1851-9. PubMed ID: 15343012 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance of fibrotic, haemostatic and endotoxic changes in patients with liver cirrhosis. Li CJ; Yang ZH; Lu FG; Shi XL; Liu DL Acta Gastroenterol Belg; 2018; 81(3):404-409. PubMed ID: 30350529 [TBL] [Abstract][Full Text] [Related]
6. Antithrombin III transfusion in patients with hepatic cirrhosis. Schipper HG; ten Cate JW Br J Haematol; 1982 Sep; 52(1):25-33. PubMed ID: 7115627 [TBL] [Abstract][Full Text] [Related]
7. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Gando S; Nanzaki S; Sasaki S; Aoi K; Kemmotsu O Crit Care Med; 1998 Dec; 26(12):2005-9. PubMed ID: 9875912 [TBL] [Abstract][Full Text] [Related]
8. Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia. Rodeghiero F; Castaman G; Gugliotta L; Mattioli Belmonte M; Falanga A; Bottasso B; Barbui T; Mannucci PM Thromb Res; 1993 Feb; 69(4):377-85. PubMed ID: 8470059 [TBL] [Abstract][Full Text] [Related]
9. Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation. Slaughter TF; Mark JB; El-Moalem H; Hayward KA; Hilton AK; Hodgins LP; Greenberg CS Blood Coagul Fibrinolysis; 2001 Jan; 12(1):25-31. PubMed ID: 11229823 [TBL] [Abstract][Full Text] [Related]
10. Alterations in antithrombin III activity and other blood coagulation parameters after retinal detachment surgery. Malukiewicz-Wiśniewska G; Kotschy M Eur J Ophthalmol; 2000; 10(4):318-23. PubMed ID: 11192840 [TBL] [Abstract][Full Text] [Related]
11. Clinical significance of haemostatic tests in chronic liver disease. Saray A; Mesihovic R; Vanis N; Gornjakovic S; Prohic D Med Arch; 2012; 66(4):231-5. PubMed ID: 22919876 [TBL] [Abstract][Full Text] [Related]
12. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Baudo F; DeGasperi A; deCataldo F; Caimi TM; Cattaneo D; Redaelli R; Pannacciulli E; Corti A; Mazza E; Belli L Thromb Res; 1992 Dec; 68(4-5):409-16. PubMed ID: 1290169 [TBL] [Abstract][Full Text] [Related]
13. Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery. Nishiyama T; Yokoyama T; Yamashita K J Anesth; 2006; 20(3):179-82. PubMed ID: 16897236 [TBL] [Abstract][Full Text] [Related]
14. No effect of cloricromen on some coagulation parameters in patients with ischaemic cerebrovascular disease. Orefice G; Grasso A; Fazio N; Del Vecchio G; Volpe G; Coppola M; D'Alessio A; Carrieri PB J Int Med Res; 1994; 22(5):287-91. PubMed ID: 7867874 [TBL] [Abstract][Full Text] [Related]
15. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation]. Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289 [TBL] [Abstract][Full Text] [Related]
16. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Ben-Ari Z; Osman E; Hutton RA; Burroughs AK Am J Gastroenterol; 1999 Oct; 94(10):2977-82. PubMed ID: 10520855 [TBL] [Abstract][Full Text] [Related]
17. Protein C and D-dimer are related to portal vein thrombosis in patients with liver cirrhosis. Zhang D; Hao J; Yang N J Gastroenterol Hepatol; 2010 Jan; 25(1):116-21. PubMed ID: 19686413 [TBL] [Abstract][Full Text] [Related]
18. Deficient antithrombin III activity and enhanced fibrinolysis in patients with liver disease: evidence against a cause-effect relationship. Pirisi M; Fabris C; Ceriello A; Soardo G; Giacomello R; Toniutto P; Vitulli D; Gonano F; Bartoli E Acta Gastroenterol Belg; 1995; 58(2):230-7. PubMed ID: 7571984 [TBL] [Abstract][Full Text] [Related]
19. Thromboelastographic changes in liver and pancreatic cancer surgery: hypercoagulability, hypocoagulability or normocoagulability? De Pietri L; Montalti R; Begliomini B; Scaglioni G; Marconi G; Reggiani A; Di Benedetto F; Aiello S; Pasetto A; Rompianesi G; Gerunda GE Eur J Anaesthesiol; 2010 Jul; 27(7):608-16. PubMed ID: 20389262 [TBL] [Abstract][Full Text] [Related]
20. Copper concentrations are prevalently associated with antithrombin III, but also with prothrombin time and fibrinogen in patients with liver cirrhosis: A cross-sectional retrospective study. Tarantino G; Citro V; Capone D; Gaudiano G; Sinatti G; Santini SJ; Balsano C J Trace Elem Med Biol; 2021 Dec; 68():126802. PubMed ID: 34091123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]